# First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers

> **NCT03482648** · PHASE1 · COMPLETED · sponsor: **Bridge Biotherapeutics, Inc.** · enrollment: 80 (actual)

## Conditions studied

- Ulcerative Colitis

## Interventions

- **DRUG:** BBT-401-1S, Single dose
- **DRUG:** BBT-401-1S, Multiple doses
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT03482648
- **Lead sponsor:** Bridge Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-03-20
- **Primary completion:** 2018-09-26
- **Final completion:** 2018-10-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2021-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03482648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03482648, "First-In-Human Study of BBT-401-1S Following Single and Multiple Ascending Doses in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03482648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*